1 Herd immunity thresholds for SARS-CoV-2 estimated from

2 unfolding epidemics

- 3 Ricardo Aguas¹, Jessica G. King², Guilherme Gonçalves³, Marcelo U. Ferreira⁴, M.
- 4 Gabriela M. Gomes⁵*
- ⁵ ¹ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
- 6 University of Oxford, Oxford, United Kingdom.
- 7 ² Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, United
- 8 Kingdom.
- 9 ³ Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências
- 10 Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
- ⁴ Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
- ⁵ Department of Mathematics and Statistics, University of Strathclyde, Glasgow,
- 13 United Kingdom.
- 14
- ^{*} Correspondence and requests for materials should be addressed to M.G.M.G. (email:
- 16 gabriela.gomes@strath.ac.uk).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Variation in individual susceptibility or exposure to infection accelerates the rate 18 at which populations acquire immunity by natural infection. Individuals that are 19 more susceptible or more exposed tend to be infected earlier and hence 20 selectively removed from the susceptible pool, decelerating the incidence of new 21 infections. Eventually, susceptible numbers become low enough to prevent epidemic growth or, in other words, the herd immunity threshold is reached. 22 23 Here we fit epidemiological models, with inbuilt distributions of susceptibility or 24 exposure, to SARS-CoV-2 epidemics in Spain and Portugal, to estimate basic 25 reproduction numbers (R_0) alongside coefficients of individual variation (CV) 26 and the effects of control measures. Herd immunity thresholds are then calculated as $1 - (1/R_0)^{1/(1+CV^2)}$ or $1 - (1/R_0)^{1/(1+2CV^2)}$, depending on 27 28 whether variation is in susceptibility or exposure. Our inferences result in lower 29 herd immunity thresholds than what would be expected if population immunity 30 was to be induced by random infection or vaccination, $1 - 1/R_0$.

32 Introduction

33	Selection acting on unmeasured individual variation is a well-known source of bias in
34	the analysis of populations. It has been shown to affect measured rates of mortality
35	(Keyfitz and Littman; Vaupel et al 1979; Vaupel and Yashin 1985), the survival of
36	endangered species (Kendall and Fox 2002; Jenouvrier et al 2018), the scope of
37	neutral theories of biodiversity and molecular evolution (Steiner and Tuljapurkar
38	2012, Gomes et al 2019), the risk of diseases whether non-communicable (Aalen et al
39	2015; Stensrud and Valberg 2017) or infections (Anderson et al 1986; Dwyer et al
40	1997; Smith et al 2005; Bellan et al 2015; Gomes et al 2019; Corder et al 2020), and
41	the efficacy of interventions such as vaccines (Halloran et al 1996; O'Hagan et al;
42	Gomes et al 2014; Gomes et al 2016; Langwig et al 2017) or symbionts (Pessoa et al
43	2016; King et al 2018). Building on this knowledge, we addressed how selection on
44	individual variation might affect the course of the coronavirus disease (COVID-19)
45	pandemic (Gomes et al 2020).
46	COVID-19 is an infectious respiratory disease caused by a virus (severe acute
10	covid-1) is an infectious respiratory disease caused by a virus (severe acute
47	respiratory syndrome coronavirus 2 [SARS-CoV-2]), which was first identified in
48	China in late 2019 and has since spread worldwide leading to considerable human
49	suffering and social disruption. European and American continents have been the
50	most affected, with 0.16% and 0.20% of the respective total populations having died
51	as of the 15 July 2021 (WHO 2021). Here we analyse series of daily deaths attributed
52	to COVID-19 in Spain and Portugal (Iberian Peninsula) to study how individual
53	variation in susceptibility and exposure to a respiratory virus affects its epidemic
54	trajectory. Besides adding to the compendium of neglected effects of selection in

55 population dynamics we hope to stimulate a new approach to study epidemic

56 dynamics.

57	The main idea developed here is that individual variation in susceptibility or exposure
58	(connectivity) accelerates the acquisition of immunity in populations. More
59	susceptible and more connected individuals have a higher propensity to be infected
60	and thus are likely to become immune earlier. Due to this selective immunization by
61	natural infection, heterogeneous populations acquire herd immunity by natural
62	infection more efficiently than suggested by models that do not fully account for these
63	types of variation. We integrate continuous distributions of susceptibility or
64	connectivity in otherwise basic epidemiological models for COVID-19, which
65	necessarily account for non-pharmaceutical intervention effects, and generate three
66	types of results. First, at national levels the herd immunity threshold by natural
67	infection declines from around 70% to 20-30%. This is newly reported here for Spain
68	and in agreement with recent estimates for England and Scotland (Gomes et al 2021).
69	Second, these inferences can be made relatively early in the pandemic, such as
70	between first and second waves, provided the first wave is sufficiently large and
71	spatially synchronous. Third, we include a selection of results for Portugal to illustrate
72	how the inferential procedure degenerates when national data do not meet certain
73	conditions.

74 Individual variation in SARS-CoV-2 transmission

SARS-CoV-2 is transmitted primarily by respiratory droplets and modelled as a
 susceptible-exposed-infectious-recovered (SEIR) process.

77 Variation in susceptibility to infection

- 78 Individual variation in susceptibility is integrated as a continuously distributed factor
- that multiplies the force of infection upon individuals (Diekmann et al 1990) in the
- 80 form of an infinite system of ordinary differential equations (ODEs):

81
$$S(x) = -\lambda x S(x),$$
 (1)

82
$$\dot{E}(x) = \lambda x [S(x) + \sigma R(x)] - \delta E(x),$$
 (2)

83
$$\dot{I}(x) = \delta E(x) - \gamma I(x), \qquad (3)$$

84
$$\dot{R}(x) = (1 - \phi)\gamma I(x) - \sigma \lambda x R(x), \qquad (4)$$

85 where S(x) is the density of individuals with susceptibility x, E(x) and I(x) are the 86 densities of individuals who originally had susceptibility x and became exposed and 87 infectious, while R(x) represents those who have recovered and have their 88 susceptibility reduced to a reinfection factor σ due to acquired immunity. Parameter δ 89 is the rate of progression from exposed to a period of maximal infectiousness (= 90 1/5.5 per day [McAloon et al. 2020]). ν is the rate of recovery from maximal infectiousness (= 1/4 per day [Nishiura et al. 2020; Lauer et al. 2020; Li et al. 91 92 2020]), ϕ is the proportion of individuals who die as a result of infection (= 0.009 93 [Ward et al. 2021]), and:

94
$$\lambda = \frac{\beta}{N} \int \rho E(y) + I(y) \, dy$$
(5)

is the average force of infection upon susceptible individuals in a population of approximately constant size N and transmission coefficient β . Standardizing so that susceptibility distributions have mean $\int xg(x) dx = 1$, given a probability density function g(x), the basic reproduction number, defined as the expected number of secondary infections generated by an infected individual in a population that has no specific immunity to the virus (Diekmann et al 1990), is:

101
$$\mathcal{R}_0 = \beta \left(\frac{\rho}{\delta} + \frac{1}{\gamma}\right),$$
 (6)

102 where ρ is a factor measuring the infectiousness of individuals in compartment *E* in

103 relation to those in I (= 0.5[Wei et al. 2020; To et al. 2020; Arons et al. 2020; He et

al. 2020]). The coefficient of variation in individual susceptibility CV =

105 $\sqrt{\int (x-1)^2 g(x) dx}$ is also treated as a parameter.

106 The basic reproduction number \mathcal{R}_0 is a theoretical framework. It cannot be exactly

107 measured directly but it can be approximated from the initial growth in case numbers.

108 However, as the virus spreads through the population, infected and immune

109 individuals accumulate, reducing the availability of susceptible hosts. As a result,

- 110 growth in case numbers deviates from being a direct indication of \mathcal{R}_0 but rather of a
- 111 so-called effective reproduction number \mathcal{R}_{eff} .
- 112 When susceptibility is given by a gamma distribution and acquired immunity is
- 113 totally protective, the effective reproduction number is:

114
$$\mathcal{R}_{eff}(t) = \mathcal{R}_0 \left(\frac{S(t)}{N}\right)^{1+CV^2},$$
(7)

115 where $S(t) = \int S(x, t) dx$ is the total number of susceptible individuals at time *t*, and 116 (Equations 1-4) reduce to a finite system of ODEs:

117
$$\dot{S} = -\beta (\rho E + I) \left(\frac{S}{N}\right)^{1+CV^2}$$
, (8)

118
$$\dot{E} = \beta \left(\rho E + I\right) \left(\frac{S}{N}\right)^{1+CV^2} - \delta E,$$
(9)

$$119 \quad \dot{I} = \delta E - \gamma I,\tag{10}$$

120
$$\dot{R} = (1 - \phi)\gamma I, \tag{11}$$

- 121 where *S*, *E*, *I* and *R* are the total numbers of susceptible, exposed, infectious and
- 122 recovered individuals, respectively (Novozhilov 2008; Montalbán et al. 2020).
- 123 Variation in connectivity
- 124 In a directly transmitted infectious disease, such as COVID-19, variation in exposure
- 125 to infection is primarily governed by patterns of connectivity among individuals. Here
- 126 we incorporate this in the system (Equations 1-4) under the assumption that
- 127 individuals mix at random (Pastor-Satorras and Vespignani 2001; Miller et al. 2012),
- 128 while in Supplementary Information we conduct some sensitivity analyses to this
- 129 assumption. Under random mixing and heterogeneous connectivity, the force of
- 130 infection is written as:

131
$$\lambda = \frac{\beta}{N} \frac{\int y[\rho E(y) + I(y)] \, dy}{\int yg(y) \, dy},$$
(12)

132 and the basic reproduction number is:

133
$$\mathcal{R}_0 = (1 + CV^2)\beta\left(\frac{\rho}{\delta} + \frac{1}{\gamma}\right). \tag{13}$$

134 In this setup, when connectivity is given by a gamma distribution and acquired

immunity is totally protective, the effective reproduction number is:

136
$$\mathcal{R}_{eff}(t) = \mathcal{R}_0 \left(\frac{S(t)}{N}\right)^{1+2CV^2},$$
(14)

137 and (Equations 1-4) reduce to the finite system of ODEs:

138
$$\dot{S} = -(1 + CV^2)\beta(\rho E + I)\left(\frac{S}{N}\right)^{1+2CV^2}$$
, (15)

139
$$\dot{E} = (1 + CV^2)\beta(\rho E + I)\left(\frac{S}{N}\right)^{1+2CV^2} - \delta E,$$
 (16)

$$140 \quad \dot{I} = \delta E - \gamma I, \tag{17}$$

141
$$\dot{R} = (1 - \phi)\gamma I, \tag{18}$$

142 where S, E, I and R are the total numbers of susceptible, exposed, infectious and

- 143 recovered individuals, respectively (Novozhilov 2008; Montalbán et al. 2020).
- 144 We have used the reduced systems (Equations 8-11) and (Equations 15-18) in
- 145 combination with non-pharmaceutical interventions (NPIs) to analyse series of daily
- 146 deaths in the study countries.

153

147 Non-pharmaceutical interventions and other transmissibility modifiers

- 148 NPIs designed to control transmission typically reduce β and hence \mathcal{R}_0 . Denoting the
- 149 time-dependent reproduction number when control measures are in place by $\mathcal{R}_c(t)$,
- 150 the modified effective reproduction number is obtained by replacing \mathcal{R}_0 with $\mathcal{R}_c(t)$ in
- 151 (Equation 7) and (Equation 14) as appropriate. For the estimation of $\mathcal{R}_c(t)$ we
- 152 introduce flexible transmissibility profiles c(t) as illustrated in Figure 1.



154 Figure 1: Transmissibility profile. Schematic illustration of factor c(t) representing 155 the combined effects of NPIs, seasonality and viral evolution on the reproduction 156 number $\mathcal{R}_{c}(t)$. T_{0} is the time when \mathcal{R}_{0} begins to decrease due to behavioural change or seasonality; T_1 is the time interval over which transmission reduces gradually until 157 158 the first lockdown; $c_1 \leq 1$ is the average c(t) achieved during the first lockdown; L_1 , 159 L_2 and L_3 , denote the length in days of the successive periods of strictest NPI 160 measures (L_1 being the first lockdown). These profiles are adopted in fits until: 1 July 161 2020 (top); 1 March 2021 (bottom).

162 One-wave transmissibility profile

163 When the model is applied to the first pandemic wave only (until 1 July 2020) we use 164 the top profile in Figure 1. T_0 is the time when \mathcal{R}_0 begins to decrease due to 165 behavioural change or seasonality; T_1 is the time interval over which transmission 166 reduces gradually (assumed linearly, until the first lockdown; $c_1 \leq 1$ is the average 167 c(t) from the beginning of the first lockdown onwards (14 March in Spain, 19 March

168 in Portugal). Mathematically this is constructed as:

169
$$c(t) = \begin{cases} 1, & \text{if } 0 < t \le T_0, \\ 1 - (1 - c_1) \cdot \frac{(1 - T_0)}{T_1}, & \text{if } T_0 < t \le T_0 + T_1, \\ c_1, & \text{otherwise.} \end{cases}$$
(19)

170 *Two-wave transmissibility profile*

171 Applying the model over longer periods which capture multiple waves and multiple 172 lockdowns requires additional features on the transmissibility profile. Denoting by L_1 173 the duration of the first lockdown (29 days in Spain, 44 days in Portugal), we allow 174 restrictions to be progressively relaxed at the end of this period by letting transmission 175 begin a linear increase such that c(t) reaches 1 in T_2 days, which may or may not be 176 within the range of the study. Changes in other factors that affect transmission (such 177 as seasonality or viral evolution) are inseparable from contact changes in this 178 framework and are also accounted for by c(t). Mathematically this is constructed as:

$$179 c_0(t) = \begin{cases} 1, & \text{if } 0 < t \le T_0, \\ 1 - (1 - c_1) \cdot \frac{(1 - T_0)}{T_1}, & \text{if } T_0 < t \le T_0 + T_1, \\ c_1, & \text{if } T_0 + T_1 < t \le T_0 + T_1 + L_1, \\ 1 - (1 - c_1) \cdot \frac{(T_0 + T_1 + L_1 + T_2 - t)}{T_1}, & \text{otherwise.} \end{cases}$$

$$(20)$$

180 Second and third lockdowns in the autumn and winter season are implemented as a

181 further reduction in transmission (by factors c_2 and c_3 , respectively) over the

182 stipulated time periods (L_2 and L_3 in the bottom panel of Figure 1):

183
$$c_{\text{Spain}}(t) = \begin{cases} c_2 \cdot c_0(t), & \text{if } t \in [26 \text{ October 2020, 22 December 2020}], \\ c_3 \cdot c_0(t), & \text{if } t \in [7 \text{ January 2021, last data point}], \\ c_0(t), & \text{otherwise.} \end{cases}$$
(21)

184
$$c_{\text{Portugal}}(t) = \begin{cases} c_2 \cdot c_0(t), & \text{if } t \in [9 \text{ November 2020, 21 December 2020}], \\ c_3 \cdot c_0(t), & \text{if } t \in [14 \text{ January 2021, last data point}], \\ c_0(t), & \text{otherwise.} \end{cases}$$
 (22)

185 In Spain, second and third lockdowns were effectively a single intervention mildly interrupted 186 by a short relaxation over Christmas, and hence we assume $c_2 = c_3$ in this country. This is

187 contrasted by Portugal where the third lockdown was much stricter than the second.

188 Herd immunity thresholds

189 Individual variation in risk of acquiring infection is under selection by the force of

190 infection, whether individual differences are due to biological susceptibility,

- 191 exposure, or both. The most susceptible or exposed individuals are selectively
- removed from the susceptible pool as they become infected and eventually recover
- 193 with immunity (some die), resulting in decelerated epidemic growth and accelerated
- 194 acquisition of immunity in the population. The herd immunity threshold (HIT) defines
- 195 the percentage of the population that needs to be immune to reverse epidemic growth
- and prevent future waves. In the absence of NPIs or other transmissibility modifiers,

- 197 if individual susceptibility or connectivity is gamma-distributed and mixing is
- 198 random, basic HIT curves (\mathcal{H}_0) can be derived analytically (Montalbán et al 2020)

199 from the model systems (Equations 1-4, with the respective forces of infections). In

200 the case of variation in susceptibility to infection we obtain

201
$$\mathcal{H}_0 = 1 - \left[\frac{1 - \sigma R_0}{(1 - \sigma)R_0}\right]^{\frac{1}{1 + CV^2}}$$
, (23)

202 while variable connectivity results in

203
$$\mathcal{H}_0 = 1 - \left[\frac{1 - \sigma R_0}{(1 - \sigma)R_0}\right]^{\frac{1}{1 + 2CV^2}}$$
 (24)

In less straightforward cases, such as when the characteristics follow a distribution other than gamma (Gomes et al. 2020), when mixing is not random (Supplementary Information), when both distributions in susceptibility and connectivity are considered, or when contact networks are rewired as result of NPIs or otherwise, \mathcal{H}_0 can be obtained numerically.

209 Both (Equation 23) and (Equation 24) convey substantial declines in HIT as

210 individual variation increases (Figure 2, Gomes et al. 2020), most strikingly over

211 relatively low CV (from 0 up to 1 or 2). For concreteness, when $\mathcal{R}_0 = 3$, $\mathcal{H}_0 = 67\%$

for CV = 0, while CV = 1 brings \mathcal{H}_0 down to 42% for heterogeneous susceptibility

- and 30% for heterogeneous connectivity, and CV = 2 brings \mathcal{H}_0 further down to 20%
- and 11%, respectively. Accounting for reinfection (i.e. $\sigma > 0$ in the formulas) might
- 215 moderate these reductions. In any case, such differences in HIT are an indication of
- 216 strong sensitivity of the epidemic dynamics to the parameter CV. Since early in the
- 217 COVID-19 pandemic we and others (Gomes et al. 2020, Britton et al 2020) have

- advocated for attention to this issue. Given that the steeper decline in \mathcal{H}_0 appears to
- 219 occur over a range of realistic CVs (Gomes et al. 2020, Gomes et al 2021) it is
- 220 plausible that some aspects of the pandemic dynamics need to be reinterpreted in a
- broader framework.



Figure 2: Herd immunity threshold and epidemic final size. Herd immunity thresholds (solid curves) are calculated according to (Equation 23) for heterogeneous susceptibility and (Equation 24) for heterogeneous connectivity. Final sizes of the corresponding unmitigated epidemics are also shown (dashed). Curves are generated for different values of the efficacy of immunity conferred by natural infection $(1 - \sigma)$ as displayed in the legend.

- 229 We emphasise, however, that \mathcal{H}_0 is a theoretical framework almost to the extent that
- 230 \mathcal{R}_0 is a theoretical framework. It cannot be measured directly when epidemic
- trajectories are affected by interventions, but it can be inferred indirectly from
- 232 epidemiological data. By construction, \mathcal{H}_0 changes if the parameters that determine
- 233 its value change. Most notably, natural changes in \mathcal{R}_0 through time, which can
- happen due to seasonal forces or viral evolution, transfer to \mathcal{H}_0 according to

235 (Equation 23), (Equation 24), or even their homogeneity equivalent $1 - 1/\mathcal{R}_0$. As a

result, the percentage of the population immune required to prevent sustained

237 epidemic growth may deviate from the initial \mathcal{H}_0 . Notwithstanding, a model with

lower \mathcal{H}_0 outputs smaller epidemics than a model with higher \mathcal{H}_0 , all non-basic

239 processes being the same.

240 The phenomenon of variation and selection which accounts for lower HIT was widely

241 explained around mid-2020 (Hartnett 2020) and generated broad public interest in the

context of COVID-19. By early 2021, vaccines had become available, and the

243 narrative changed to imply that the HIT might be unachievable for COVID-19

244 (Aschwanden 2021). This apparent contradiction stems from the adoption of less

245 fundamental meaning of HIT by the latter. While Hartnett (2020) writes about using

246 the basic \mathcal{H}_0 to assess pandemic potential, stressing how that is weakened by

247 variation and selection by natural infection, Aschwanden (2021) endorses a more

248 common sensical view that reinfection may become frequent enough to make herd

249 immunity unachievable. In the light of the theory presented here – specifically

250 (Equation 23) and (Equation 24) – these views are transversal and not contradictory.

251 Data

We fit compartmental models to publicly available epidemiological data from the coronavirus dashboards for Spain [https://cnecovid.isciii.es/covid19] and Portugal

254 [https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal] to fit the models

and estimate parameters of interest. Namely, we fit model reconstructed mortality

timeseries assuming a fixed infection fatality ratio to datasets containing daily deaths,

257 $\{(k, \tilde{y}_k)\}_{k=1}^n$, where k = 1 is the day when the cumulative moving average of death

numbers exceed $5 \cdot 10^{-7}$ of the population (7 March in Spain, 19 March 2020 in

259 Portugal).

Model fits were carried out to the raw series of daily deaths until the 1 July 2020 in the first instance (to cover the first wave of the epidemic in the study countries), and until the 1 March 2021 in an extended analysis (as a compromise between having a series sufficiently long to capture much of the second wave and not so long that it would be affected by vaccination and require the vaccine to be modelled). We defined the initial conditions as:

$$266 R(0) = 0, (25)$$

267
$$I(0) = \frac{\tilde{y}_{1+\eta}}{1 - \exp(-\phi\gamma)},$$
 (26)

268
$$E(0) = \frac{I(0)}{1 - \exp(-\gamma)},$$
 (27)

269
$$S(0) = N - E(0) - I(0) - R(0),$$
 (28)

and the population sizes N were obtained from the most recent respective census

271 (approx. 46.94 million in Spain, 10.28 million in Portugal, 3.57 million in the North

272 Region of Portugal, 3.66 million in Lisbon and Tagus Valley Region of Portugal).

273 Model fitting and parameter estimating

274 We assumed that reinfection was negligible throughout the study period. A study

conducted in England (Hall et al. 2021), between June 2020 and January 2021,

- 276 concluded that previous SARS-CoV-2 infection induced 84% effective immunity to
- future infections. In (Gomes et al. 2121) we fit models to daily COVID-19 deaths in
- 278 England and Scotland, assuming no reinfection (i.e. 100% effective immunity) or
- 279 90% effective immunity, and found this alteration to have no significant effect on

projected model trajectories. Basically, the fit readjusts the parameters when reinfection is added to the model in such a way that the output solutions remain similar.

- 283 Parameter estimation was performed with the software MATLAB using the PESTO
- 284 (Parameter EStimation Toolbox) package (Stapor et al. 2018). We assumed the

285 number of SARS-CoV-2 infections to be Poisson distributed.

286 We approximate the dynamics of COVID-19 deaths by estimating the set of

287 parameters θ that maximises the log-likelihood (LL) of observing the daily numbers

of reported deaths *Y*:

289
$$LL(\theta|Y) = -\sum_{k=1}^{n} y(k,\theta) + \sum_{k=1}^{n} \tilde{y}(k) \ln(y(k,\theta)) - \sum_{k=1}^{n} \ln(\tilde{y}(k)!),$$
 (29)

where $y(k, \theta)$ are the simulated model output numbers of COVID-19 deaths at day kfor the set of parameters θ , $Y = \{(k, \tilde{y}_k)\}_{k=1}^n$ are the numbers of daily reported deaths, and n is the total number of days included in the analysis.

293 Fitting models to one pandemic wave

294 The models exploring heterogeneity in susceptibility (Equations 8-11) and

- connectivity (Equations 15-18) both with transmissibility profile as in (Equation 19)
- were fit to COVID-19 deaths recorded daily until 1 July 2020, in Spain and Portugal.
- A homogeneous version obtained by setting CV = 0 in either model was also fitted.
- 298 Results for Spain are shown in Table 1 and Figure 3, and for Portugal in Table 2 and

299 Figure 4.

300 We estimate the basic reproduction number \mathcal{R}_0 with 95% credible intervals (CI)

301 around 3.5 - 3.8 in Spain and 2.3 - 3.4 in Portugal. For the minimal transmissibility

302 factor c_1 we estimate 0.21 - 0.27 when individual variation is allowed and 0.18 -

303 0.19 with the homogeneity constraint in Spain, while in Portugal we estimate the

304 wider intervals 0.26 - 0.39. For coefficients of variation in Spain, we estimate CV in

305 the range 1.3 - 2.4 under heterogeneous susceptibility and 1.0 - 1.7 under

306 heterogeneous connectivity. In Portugal, we obtain the much wider and uninformative 307 ranges 0.0 - 3.2.

308 Left plots in Figures 3 and 4 show the best fitting model solutions generated from the

309 median posterior estimates of each parameter in the respective countries as well as the

310 95% CI generated from 100,000 posterior samples. The basic herd immunity

311 thresholds \mathcal{H}_0 , calculated from \mathcal{R}_0 and CV estimates, are $\mathcal{H}_0 = 19\%$ (95% CI, 13-

312 32%) under heterogeneous susceptibility, $\mathcal{H}_0 = 19\%$ (95% CI, 13-36%) under

heterogeneous connectivity, and $\mathcal{H}_0 = 72\%$ (95% CI, 71-73%) when homogeneity is

imposed, in Spain. In Portugal, we obtain $\mathcal{H}_0 = 19\%$ (95% CI, 5-69%) under

heterogeneous susceptibility, $\mathcal{H}_0 = 13\%$ (95% CI, 3-69%) under heterogeneous

316 connectivity, and $\mathcal{H}_0 = 67\%$ (95% CI, 66-69%) when homogeneity is imposed.

317 Credible intervals for \mathcal{H}_0 in Portugal are wide and uninformative when individual

318 variation is allowed which is expected given the wide ranges obtained for CV. NPIs in

319 Portugal were initiated very early in the epidemic which resulted in transmissibility

320 reductions blending with \mathcal{R}_0 , making parameter identification a major challenge from

321 the data accessible to us.

322 In Spain, where the three models provide good fits to the data, model selection criteria

323 such as AIC (Akaike information criterion) support the heterogeneous

324	implementations. To better distinguish the various models, we run the respective
325	systems of equations forward, under a set of conventions, and compare the respective
326	projected outcomes. Right plots in Figures 3 were generated by taking the end
327	conditions of the left plots, moving all exposed and infectious individuals to
328	recovered (except a residual proportion to seed a new outbreak) and running each
329	model with the estimated \mathcal{R}_0 and CV until the susceptible pool has been effectively
330	depleted in all implementations. In this manner we can visualise how much more
331	infection appears to be ahead when models are constrained to be homogeneous (a
332	manifestation of their relatively higher \mathcal{H}_0 . Roughly, epidemics peak one order of
333	magnitude higher when models are homogeneous. This must have broad implications,
334	which we believe remain largely unappreciated, for how a population will experience
335	an epidemic, irrespective of how this basic scenario is adapted to specific factors such
336	behavioural patterns, seasonality, viral evolution, or vaccination.
337	The same analysis applied to Portugal, selects in favour of the homogeneity

- 338 assumption and larger projected waves. We recall, however, the great uncertainty
- 339 associated with these specific results. We investigate this further through fittings to
- 340 longer data series, in the first instance.

341**Table 1: Model parameters for Spain (one wave).** Estimated by Bayesian inference342based on daily deaths until 1 July 2020. Model selection based on maximum log-343likelihood (LL) and Akaike information criterion (AIC). Best fitting models have344lower AIC scores (best in red, second best in blue). Herd immunity threshold (\mathcal{H}_0)345derived from estimated \mathcal{R}_0 and CV.

	Heterogeneous susceptibility		Heterogeneous connectivity		Homogeneous		
	Median	95% CI	Media n	95% CI	Media n	95% CI	
	Estimated parameters						
T_0	5.44	[3.52, 6.07]	5.40	[3.45, 6.07]	5.48	[3.73, 6.04]	
<i>c</i> ₁	0.24	[0.21, 0.27]	0.24	[0.21, 0.28]	0.18	[0.18, 0.19]	
η	16^{*}	[15.53, 16.47]	16^{*}	[15.52, 16.48]	16^{*}	[15.52, 16.47]	
\mathcal{R}_{0}	3.59	[3.51, 3.79]	3.59	[3.51, 3.80]	3.53	[3.47, 3.71]	

CV	1.98	[1.33, 2.44]	1.41	[0.97, 1.74]	0	-	
		Derivea	l from esti	mated parameters	7		
\mathcal{H}_{0}	23%	[17%, 38%]	23%	[16%, 37%]	72%	[71%, 73%]	
	Model selection						
LL		-503.78		-503.50		-518.33	
AIC		1017.60		1017.00		1044.70	

^{*} Rounded median resulting in integer number of days.

347	Table 2: Model	parameters for l	Portugal (one	wave). Estimated	l by Bayesian
-----	----------------	-------------------------	---------------	------------------	---------------

348 inference based on daily deaths until 1 July 2020. Model selection based on maximum

349 log-likelihood (LL) and Akaike information criterion (AIC). Best fitting models have

lower AIC scores (best in red, second best in blue). Herd immunity threshold (\mathcal{H}_0)

351 derived from estimated \mathcal{R}_0 and CV.

	Het	Heterogeneous		Heterogeneous		Homogeneous		
	sus	ceptibility	cc	onnectivity		8		
	Median	95% CI	Media n	95% CI	Media n	95% CI		
	Estimated parameters							
T_0	0.05	[0.00, 0.10]	0.05	[0.00, 0.10]	0.05	[0.00, 0.10]		
C_1	0.31	[0.26, 0.36]	0.32	[0.26, 0.39]	0.31	[0.26, 0.35]		
η	20^{*}	[14.75, 25.72]	20^{*}	[13.27, 25.94]	21^{*}	[15.56, 26.04]		
\mathcal{R}_{0}	2.62	[2.29, 3.21]	2.66	[2.27, 3.39]	2.61	[2.28, 3.15]		
ĊŇ	0.31	[0.01, 3.24]	0.38	[0.01, 3.04]	0	-		
Derived from estimated parameters								
\mathcal{H}_0	58%	[7%, 69%]	53%	[4%, 70%]	62%	[56%, 68%]		
			Model s	election				
LL		-287.10	-287.14		-287.34			
AIC		584.20		584.28		582.67		

^{*} Rounded median resulting in integer number of days.



353

354 Figure 3: Estimating SARS-CoV-2 transmission in Spain by fitting one wave of

355 **COVID-19 deaths.** Variation in susceptibility (top panels); variation in connectivity 356 (middle panels); and homogeneous model (bottom panels). Susceptibility or

357 connectivity factors implemented as gamma distributions. Controlled (R_c) and

effective (R_{eff}) reproduction numbers are displayed on shallow panels underneath the

359 main plots. Basic reproduction number, coefficients of variation and transmissibility

- 360 profile parameters estimated by Bayesian inference as described in Methods
- 361 (estimates in Table 1). Curves represent model reconstructions from the median

362 posterior parameter estimates. Shades represent 95% credible intervals from 100,000

363 posterior samples.



365 Figure 4: Estimating SARS-CoV-2 transmission in Portugal by fitting one wave of **COVID-19 deaths.** Variation in susceptibility (top panels); variation in connectivity 366 (middle panels); and homogeneous model (bottom panels). Susceptibility or 367 connectivity factors implemented as gamma distributions. Controlled (R_c) and 368 369 effective (R_{eff}) reproduction numbers are displayed on shallow panels underneath the 370 main plots. Basic reproduction number, coefficients of variation and transmissibility 371 profile parameters estimated by Bayesian inference as described in Methods 372 (estimates in Table 2). Curves represent model reconstructions from the median 373 posterior parameter estimates. Shades represent 95% credible intervals from 100,000 374 posterior samples.

375 Fitting models to two serial pandemic waves

- 376 Here we take the models with heterogeneity in susceptibility (Equations 8-11) and
- 377 connectivity (Equations 15-18) and apply the transmissibility profile in (Equations
- 378 20-22) to both before fitting the model outputs to COVID-19 deaths recorded daily
- until 1 March 2021, in Spain and Portugal. As before a homogeneous version
- obtained by setting CV = 0 was also fitted. Results for Spain are shown in Table 3
- and Figure 5, and for Portugal in Table 4 and Figure 6.
- 382 We estimate \mathcal{R}_0 with 95% CI around 3.9 4.4 in Spain and 2.7 4.6 in Portugal.
- 383 For the minimal transmissibility factor c_1 we estimate 0.20 0.21 when individual
- 384 variation is allowed and 0.17 with the homogeneity constraint in Spain, while in
- 385 Portugal we obtain 0.23 0.32 with individual variation and 0.16 0.18 without. For
- 386 coefficients of variation in Spain, we estimate CV around 2.0 under heterogeneous
- 387 susceptibility and 1.3 under heterogeneous connectivity. In Portugal, the estimates are
- 388 around 0.5.
- 389 Left plots in Figures 5 and 6 show best fitting model solutions as well as the
- 390 respective 95% CI. In Spain, basic herd immunity thresholds calculated from best-
- fitting \mathcal{R}_0 and CV are $\mathcal{H}_0 = 25\%$ under heterogeneous susceptibility, $\mathcal{H}_0 = 27\%$
- 392 under heterogeneous connectivity, and $\mathcal{H}_0 = 76\%$ when homogeneity is imposed. In

393	Portugal,	we obtain again	wider and higher	ranges: $\mathcal{H}_0 =$	56% (95%	CI, 52-57%)
-----	-----------	-----------------	------------------	---------------------------	----------	-------------

- 394 under heterogeneous susceptibility, $\mathcal{H}_0 = 56\%$ (95% CI, 54-57%) under
- heterogeneous connectivity, and $\mathcal{H}_0 = 77\%$ (95% CI, 76-78%) when homogeneity is
- 396 imposed.
- 397 Puzzling, as in the case of shorter data series, model selection supports the
- 398 homogeneous model for Portugal while still favouring the incorporation of individual
- 399 variation in Spain. Moreover, for each country, results are consistent whether we base
- 400 our estimates on one or two waves of the national epidemic. This consistency was
- 401 also verified in England and Scotland (Gomes et al 2021). This suggests that the
- 402 earlier initiation of NPI in Portugal may not in itself explain why results for Portugal
- 403 contrast with those for other countries studied.

404 **Table 3: Model parameters for Spain (two waves).** Estimated by Bayesian

405 inference based on daily deaths until 1 March 2021. Model selection based on

406 maximum log-likelihood (LL) and Akaike information criterion (AIC). Best fitting

407 models have lower AIC scores (best in red, second best in blue). Herd immunity

Heteroge	Heterogeneous susceptibility		Heterogeneous connectivity		omogeneous		
Median	95% CI	Median	95% CI	Median	95% CI		
Estimated parameters							
3.22	[3.18, 3.31]	6.06	[6.06, 6.07]	5.99	[5.98, 5.99]		
448.42	[446.58, 452.53]	429.91	[427.04, 433.98]	783.88	[777.04, 784.12]		
0.20	[0.20, 0.20]	0.21	[0.21, 0.21]	0.17	[0.17, 0.17]		
0.71	[0.71, 0.71]	0.68	[0.68, 0.68]	0.50	[0.50, 0.50]		
12^{*}	[12.42, 12.50]	12^{*}	[11.54, 12.45]	10^{*}	[10.04, 10.07]		
4.36	[4.32, 4.37]	3.93	[3.92, 3.95]	4.11	[4.10, 4.11]		
2.02	[2.01, 2.02]	1.30	[1.28, 1.31]	0	-		
Derived from estimated parameters							
25%	[25%, 25%]	27%	[27%, 27 %]	76%	[76%, 76%]		
		Model	selection				
	-3511.40	-3269.90		-5826.40			
	7036.80		6553.90		11665.00		
	Heteroge Median 3.22 448.42 0.20 0.71 12* 4.36 2.02 25%	Heterogeneous susceptibility Median 3.22 [3.18, 3.31] 448.42 [446.58, 452.53] 0.20 [0.20, 0.20] 0.71 [0.71, 0.71] 12* [12.42, 12.50] 4.36 [4.32, 4.37] 2.02 [2.01, 2.02] Deriv 25% [25%, 25%]	Heterogeneous susceptibility MedianHeterogeneous MedianMedian95% CIMedian 3.22 $[3.18, 3.31]$ 6.06 448.42 $[446.58, 452.53]$ 429.91 0.20 $[0.20, 0.20]$ 0.21 0.71 $[0.71, 0.71]$ 0.68 12^* $[12.42, 12.50]$ 12^* 4.36 $[4.32, 4.37]$ 3.93 2.02 $[2.01, 2.02]$ 1.30 Derived from es 25% $[25\%, 25\%]$ 27% Model-3511.40 7036.80 429.91	Heterogeneous susceptibility MedianHeterogeneous connectivity MedianHeterogeneous connectivity Median 3.22 $[3.18, 3.31]$ 6.06 $[6.06, 6.07]$ 448.42 $[446.58, 452.53]$ 429.91 $[427.04, 433.98]$ 0.20 $[0.20, 0.20]$ 0.21 $[0.21, 0.21]$ 0.71 $[0.71, 0.71]$ 0.68 $[0.68, 0.68]$ 12^* $[12.42, 12.50]$ 12^* $[11.54, 12.45]$ 4.36 $[4.32, 4.37]$ 3.93 $[3.92, 3.95]$ 2.02 $[2.01, 2.02]$ 1.30 $[1.28, 1.31]$ Derived from estimated parameters 25% $[25\%, 25\%]$ 27% $[27\%, 27\%]$ -3511.40 -3269.90 -3269.90 7036.80 6553.90	Heterogeneous susceptibility MedianHeterogeneous connectivity MedianHeterogeneous connectivity MedianHeterogeneous connectivity Median $Median$ 95% CIMedian95% CIMedian 3.22 $[3.18, 3.31]$ 6.06 $[6.06, 6.07]$ 5.99 448.42 $[446.58, 452.53]$ 429.91 $[427.04, 433.98]$ 783.88 0.20 $[0.20, 0.20]$ 0.21 $[0.21, 0.21]$ 0.17 0.71 $[0.71, 0.71]$ 0.68 $[0.68, 0.68]$ 0.50 12^* $[12.42, 12.50]$ 12^* $[11.54, 12.45]$ 10^* 4.36 $[4.32, 4.37]$ 3.93 $[3.92, 3.95]$ 4.11 2.02 $[2.01, 2.02]$ 1.30 $[1.28, 1.31]$ 0 Derived from estimated parameters 25% $[25\%, 25\%]$ 27% $[27\%, 27\%]$ 76% Model selection-3511.40 -3269.90 7036.80 6553.90		

408 threshold (\mathcal{H}_0) derived from estimated \mathcal{R}_0 and CV.

409 * Rounded median resulting in integer number of days.

410 **Table 4: Model parameters for Portugal (two waves).** Estimated by Bayesian

411 inference based on daily deaths until 1 March 2021. Model selection based on

412 maximum log-likelihood (LL) and Akaike information criterion (AIC). Best fitting

the short (\mathcal{F}_0) derived non-estimated \mathcal{K}_0 and $\mathcal{C}_{\mathcal{V}}$.						
	Heteroge	neous susceptibility	Heteroge	Heterogeneous connectivity		omogeneous
	Median	95% CI	Median	95% CI	Median	95% CI
			Estimated	l parameters		
T_0	0.03	[0.01, 0.05]	0.04	[0.00, 0.10]	0.05	[0.00, 0.10]
T_2	585.14	[573.66, 672.90]	644.26	[615.71, 695.38]	899.67	[872.69, 946.07]
<i>c</i> ₁	0.27	[0.27, 0.32]	0.24	[0.23, 0.25]	0.17	[0.16, 0.18]
<i>C</i> ₂	0.71	[0.71, 0.87]	0.71	[0.70, 0.77]	0.66	[0.64, 0.68]
<i>C</i> ₃	0.34	[0.27, 0.48]	0.42	[0.39, 0.48]	0.35	[0.34, 0.36]
η	16^{*}	[15.52, 17.39]	14^{*}	[12.76, 15.34]	12^{*}	[11.54, 12.33]
\mathcal{R}_0	2.94	[2.66, 2.96]	3.25	[3.14, 3.32]	4.36	[4.20, 4.58]
CV	0.55	[0.54, 0.59]	0.47	[0.47, 0.49]	0	-
Derived from estimated parameters						
\mathcal{H}_{0}	56%	[52%, 57%]	56%	[54%, 57%]	77%	[76%, 78%]
			Model	selection		
LL		-1550.80		-1376.80	-1234.30	
AIC		3117.50		2769.50		2482.50
* -			1	0.1		

413 models have lower AIC scores (best in red, second best in blue). Herd immunity 414 threshold (\mathcal{H}_0) derived from estimated \mathcal{R}_0 and CV.

415 * Rounded median resulting in integer number of days.



416

417 Figure 5: Estimating SARS-CoV-2 transmission in Spain by fitting two serial

418 waves of COVID-19 deaths. Variation in susceptibility (top panels); variation in 419 connectivity (middle panels); and homogeneous model (bottom panels). Susceptibility 420 or connectivity factors implemented as gamma distributions. Controlled (R_c) and 421 effective (R_{eff}) reproduction numbers are displayed on shallow panels underneath the

- 423 profile parameters estimated by Bayesian inference as described in Methods
- 424 (estimates in Table 3). Curves represent model reconstructions from the median

425 posterior parameter estimates. Shades represent 95% credible intervals from 100,000

426 posterior samples.



428 Figure 6: Estimating SARS-CoV-2 transmission in Portugal by fitting two serial 429 waves of COVID-19 deaths. Variation in susceptibility (top panels); variation in 430 connectivity (middle panels); and homogeneous model (bottom panels). Susceptibility 431 or connectivity factors implemented as gamma distributions. Controlled (R_c) and 432 effective (R_{eff}) reproduction numbers are displayed on shallow panels underneath the 433 main plots. Basic reproduction number, coefficients of variation and transmissibility 434 profile parameters estimated by Bayesian inference as described in Methods 435 (estimates in Table 4). Curves represent model reconstructions from the median 436 posterior parameter estimates. Shades represent 95% credible intervals from 100,000 437 posterior samples.

438 Fitting models to regional data in Portugal

439 Intrigued by the puzzling results for Portugal at country level, we gathered regional 440 data. We found that the epidemic was considerably different between the two largest 441 regions: North, home to roughly one third of the Portuguese population; and Lisbon 442 and Tagus Valley, home to another third. Asynchrony of epidemic dynamics between 443 regions of similar sizes may require disaggregated analyses. We then decided to fit 444 the mortality data for the two regions simultaneously, estimating common parameters 445 to describe country-wide lockdowns, and regions-specific parameters to describe the 446 basic transmission dynamics (\mathcal{R}_0 and CV). The results are provided in Tables 5, 6 and Figures 7-9. According to these analyses, the best-fitting models include 447 448 heterogeneity.

- 449 Basic herd immunity thresholds inferred by fits to the longer series (until 1 March
- 450 2021) are around 25 34% in the North (similar as Spain, England, and Scotland)
- 451 and 47 52% in Lisbon and Tagus Valley. The higher \mathcal{H}_0 in the capital region
- 452 results from the estimation of a lower CV. This may be real and due to the more urban
- 453 character of Lisbon and Tagus Valley or, in contrast, it may be a spurious result of the
- 454 lack of a first wave in the region to inform the model. It would be interesting to

455 replicate the regional analysis in other countries to investigate to what extent more456 urban regions have higher HIT.

457	Fits to the shorter series (until 1 July 2020) are again inconclusive. Not only the
458	uncertainty around parameter estimates is large but some estimates are implausible.
459	First, \mathcal{R}_0 around 2 or less is on the low end of consensus estimates (Flaxman et al.
460	2020; Keeling et al. 2020; Viana et al. 2021; Wood 2021). More strikingly, the
461	algorithm is incapable of estimating CV from these regional series, resulting in
462	convergence to the upper and lower limits of the prior distribution (uniform between
463	$0.01 - \sqrt{12}$) in the North and Lisbon regions, respectively.
464	In summary, the results reported in this section support two notions. First,
465	asynchronous dynamics may compromise parameter estimation based on model
466	fittings to aggregated data. This should depend on whether the asynchrony in question
467	is between similar-sized regions. Second, the early estimation of parameters for
468	heterogeneous models (especially CV) may require a larger first wave than that
469	required by models that are either homogeneous (Flaxman et al. 2020; Wood 2021) or
470	have their heterogeneity informed directly by specific data (Keeling et al. 2020). The
471	downside of these other approaches, however, is that heterogeneity is either absent or
472	possibly incomplete, resulting in reduced selection and biased estimates. Among the
473	studies we have completed, England, Scotland and Spain had sufficiently sized first
474	waves to inform the inference of CV while Portugal did not.
475 476 477	Table 5: Model parameters for the North and Lisbon regions of Portugal (onewave). Estimated by Bayesian inference based on daily deaths until 1 July 2020.Model selection based on maximum log-likelihood (LL) and Akaike information

478 criterion (AIC). Best fitting models have lower AIC scores (best in red, second best in

479 blue). Herd immunity threshold (\mathcal{H}_0) derived from estimated \mathcal{R}_0 and CV.

Heterogeneous	susceptibility	Heterogeneou	s connectivity	Homo	geneous
Median	95% CI	Median	95% CI	Median	95% CI

Common parameters										
T_0	0.05	[0.00, 0.10]	0.05	[0.00, 0.10]	0.05	[0.00, 0.10]				
c_1	0.48	[0.43, 0.52]	0.55	[0.47, 0.61]	0.43	[0.40, 0.47]				
η	24^{*}	[19.45, 28.99]	21^{*}	[14.18, 27.37]	29^{*}	[28.50, 28.50]				
North										
\mathcal{R}_0	2.17	[2.00, 2.45]	2.43	[2.17, 2.92]	1.91	[1.80, 2.09]				
ĊV	3.44	[3.38, 3.46]	3.45	[3.39, 3.46]	0	-				
\mathcal{H}_{0}	5.9%	[5.2%, 7.0%]	3.5%	[3.0%, 4.4%]	48%	[44%, 52%]				
Lisbon and Tagus Valley										
\mathcal{R}_0	1.78	[1.65, 2.00]	1.65	[1.49, 1.96]	1.85	[1.74, 2.02]				
CV	0.07	[0.01, 0.56]	0.07	[0.01, 0.57]	0	-				
\mathcal{H}_{0}	44%	[32%, 50%]	39%	[21%, 49%]	46%	[43%, 51%]				
Model selection										
LL	-520.56		-479.75		-578.50					
AIC	1055.10		973.49		1167.00					

480 * Rounded median resulting in integer number of days.

481 Table 6: Model parameters for the North and Lisbon regions of Portugal (two

482 waves). Estimated by Bayesian inference based on daily deaths until 1 March 2021.

483 Model selection based on maximum log-likelihood (LL) and Akaike information

484 criterion (AIC). Best fitting models have lower AIC scores (best in red, second best in

485 blue). Herd immunity threshold (\mathcal{H}_0) derived from estimated \mathcal{R}_0 and CV.

	Heterogeneous susceptibility		Heterogeneous connectivity		Homogeneous					
	Median	95% CI	Median	95% CI	Median	95% CI				
Common parameters										
T_0	0.06	[0.00, 0.10]	0.09	[0.06, 0.10]	0.05	[0.03, 0.05]				
T_2	498.77	[489.85, 515.47]	499.41	[462.35, 547.99]	960.64	[960.28, 961.42]				
c_1	0.27	[0.26, 0.29]	0.25	[0.25, 0.25]	0.17	[0.17, 0.17]				
<i>C</i> ₂	0.75	[0.73, 0.82]	0.71	[0.69, 0.75]	0.73	[0.73, 0.73]				
<i>C</i> ₃	0.44	[0.42, 0.45]	0.49	[0.45, 0.50]	0.36	[0.36, 0.36]				
η	16^{*}	[15.36, 16.46]	15^{*}	[13.75, 15.16]	12^{*}	[11.62, 11.64]				
North										
\mathcal{R}_0	2.99	[2.88, 3.03]	3.12	[3.05, 3.18]	4.34	[4.34, 4.35]				
CV	1.40	[1.39, 1.41]	0.99	[0.93, 1.20]	0	-				
\mathcal{H}_0	31%	[30%, 31%)	32%	[25%, 34%]	77%	[77%, 77%]				
Lisbon and Tagus Valley										
\mathcal{R}_0	2.81	[2.69, 2.86]	2.95	[2.87, 3.01]	4.39	[4.38, 4.40]				
CV	0.67	[0.65, 0.70]	0.54	[0.53, 0.57]	0	-				
\mathcal{H}_{0}	51%	[49%, 52%]	49%	[47%, 51%]	77%	[77%, 77%]				
Model selection										
LL	-2313.50		-2471.00		-2764.30					
AIC		4647.10		4961.90		5544.60				

486 * Rounded median resulting in integer number of days.



488 Figure 7: Estimating SARS-CoV-2 transmission in the two larger regions of

489 **Portugal.** Heterogeneous susceptibility implemented as a gamma distribution.

490 Controlled (R_c) and effective (R_{eff}) reproduction numbers are displayed on shallow

491 panels underneath the main plots. Basic reproduction number, coefficients of

492 variation and transmissibility profile parameters estimated by Bayesian inference as493 described in Methods (estimates in Table 5). Curves represent model reconstructions

494 from the median posterior parameter estimates. Shades represent 95% credible





496

497 Figure 8: Estimating SARS-CoV-2 transmission in the two larger regions of

498 **Portugal.** Heterogeneous connectivity implemented as a gamma distribution.

499 Controlled (R_c) and effective (R_{eff}) reproduction numbers are displayed on shallow

500 panels underneath the main plots. Basic reproduction number, coefficients of

501 variation and transmissibility profile parameters estimated by Bayesian inference as

502 described in Methods (estimates in Table 5). Curves represent model reconstructions

from the median posterior parameter estimates. Shades represent 95% credibleintervals from 100,000 posterior samples.



505

506Figure 9: Estimating SARS-CoV-2 transmission in the two larger regions of507Portugal. Homogeneous model. Controlled (R_c) and effective (R_{eff}) reproduction508numbers are displayed on shallow panels underneath the main plots. Basic509reproduction number, coefficients of variation and transmissibility profile parameters510estimated by Bayesian inference as described in Methods (estimates in Table 5).511Curves represent model reconstructions from the median posterior parameter512estimates. Shades represent 95% credible intervals from 100,000 posterior samples.

513 **Discussion**

514 We fit SEIR models, with inbuilt distributions of individual susceptibility or exposure

- 515 to infection, to daily series of COVID-19 deaths in Spain and Portugal. In similarity
- 516 with other studies (Flaxman et al. 2020, Keeling et al. 2020, Bertuzzo et al. 2021,
- 517 López & Rodó 2021, Viana et al. 2021), we estimated relevant transmission
- 518 parameters, such as the basic reproduction number \mathcal{R}_0 , and a time dependent

transmissibility profile c(t) which multiplies \mathcal{R}_0 to account for effects of NPIs, seasonality, viral evolution, or any unexplicit factor that modifies the ability of the virus to infect new hosts. In contrast, our sets of estimated parameters include coefficients of variation that characterise distributions of unmeasured individual susceptibility or connectivity while more common practices are to impose measured variation into the model and ignore the unmeasured.

525 The two approaches have different advantages and disadvantages, and which to adopt 526 depends on study objectives. Using directly measured variation to inform the model 527 allows phenomena to be represented on a micro scale as desired for designing targeted 528 interventions, for instance, but ignoring unmeasured variation may create biases on 529 the macro scale if relevant selection is occurring on omitted characteristics. This may 530 result in the model overpredicting the impact of uniform interventions, for example. 531 The approach of inferring the amount of variation that is under selection by fitting the 532 model on a macro scale is conceived to eliminate those biases, but not suitable for 533 informing targeted actions. In addition, the latter approach appears to require larger 534 infected numbers than the former. In a global crisis such as the current COVID-19 535 pandemic the two approaches can have a role, helping to overcome each other's 536 limitations.

The inference of selectable variation presented here is relatively new to infectious
disease modelling. Prior to attempting this in the context of the COVID-19 pandemic,
we and others have been accelerating progress in systems that were either
experimentally controlled (Dwyer et al. 1997; Ben-Ami et al. 2008; Zwart et al. 2011;
Pessoa et al. 2014; Langwig et al. 2017; King et al. 2018) or already endemic (Smith
et al. 2005; Bellan et al. 2015; Corder et al. 2020). Several aspects of the pandemic

543 made it more challenging. There was an urgency for early results from inherently 544 scarce data, a challenge amplified by non-pharmaceutical interventions designed to 545 suppress the epidemic. In countries where interventions began earlier, such as 546 Portugal, it has been impossible to reach conclusive results without refining data and 547 methods further. In Spain (this study) and England and Scotland (Gomes et al 2021), 548 on the other hand, interventions started later, and results were consistent internally 549 and with each other. Moreover, comparing our coefficients of variation for individual 550 connectivity to those measured directly by contact surveys, we found them to be less 551 than 40% higher. This suggests that there was more selectable variation than the 552 surveys had captured, as expected, but not enough to seem implausible.

553 In conclusion, we believe that the results presented here constitute a major step in the

establishment of a novel approach to improve the accuracy and predictability of

555 infectious disease modelling. It holds good promise for use in conjunction with other

556 tools to help devise future pandemic policies.

557 Acknowledgements

- 558 We thank Jan Hasenauer, Rodrigo Corder and Antonio Montalbán for technical
- advice and contributions to related research. M.U.F. received funding from Conselho
- 560 Nacional de Desenvolvimento Científico e Tecnológio (CNPq), Brazil.

561 Author contributions

- 562 M.G.M.G. conceived the study. R.A. and M.G.M.G. performed the analyses. All
- 563 authors interpreted the data and wrote the paper.

564 **Competing interests**

565 The authors declare no competing interests.

566

567 **References**

- Keyfitz, N. & Littman, G. (1979) Mortality in a heterogeneous population. *Popul. Stud.* 33, 333-342.
- 570 2. Vaupel, J., Manton, K. & Stallard, E. (1979) Impact of heterogeneity in individual frailty
 571 on the dynamics of mortality. *Demography* 16, 439-454.
- 572 3. Vaupel, J., & Yashin, A. (1985) Heterogeneity ruses some surprising effects of
 573 selection on population dynamics. *Am. Stat.* 39, 176-185.
- 574 4. Kendall, B. E. & Fox, G. A. (2002) Variation among individuals and reduced
 575 demographic stochasticity. *Conserv. Biol.* 16, 109-116.
- 576 5. Jenouvrier, S, Aubry, L. M., Barbraud, C, Weimerskirch, H & Caswell, H. (2018)
- 577 Interacting effects of unobserved heterogeneity and individual stochasticity in the life
- 578 history of the southern fulmar. J. Anim. Ecol. 87, 212-222.
- 579 6. Steiner, U. K. & Tuljapurkar, S. (2012) Neutral theory for life histories and individual
- 580 variability in fitness components. *Proc. Natl. Acad. Sci U. S. A.* **109**, 4684-4689.
- 581 7. Gomes, M. G. M., King, J. G., Nunes, A., Colegrave, N. & Hoffmann, A. (2019) The
- 582 effects of individual nonheritable variation on fitness estimation and coexistence. *Ecol.*583 *Evol.* 16, 8995-9004.
- Aalen, O. O., Valberg, M., Grotmol, T. & Tretli, S. (2015) Understanding variation in
 disease risk: the elusive concept of frailty. *Int. J. Epidemiol.* 4, 1408-1421.
- 586 9. Stensrud, M. J. & Valberg, M. (2017) Inequality in genetic cancer risk suggests bad
 587 genes rather than bad luck. *Nat. Commun.* 8, 1165.
- 588 10. Anderson, R. M., Medley, G. F., May, R. M. & Johnson, A. M. (1986) A preliminary
- study of the transmission dynamics of the human immunodeficiency virus (HIV), the
 causative agent of AIDS. *IMA J. Math. Appl. Med. Biol.* 3, 229-263.
- 591 11. Dwyer, G., Elkinton, J. S. & Buonaccorsi, J. P. (1997) Host heterogeneity in
- 592 susceptibility and disease dynamics: Tests of a mathematical model. Am. Nat. 150, 685-
- 593 707.

- 594 12. Smith, D. L., Dushoff, J., Snow, R. W. & Hay, S. I. (2005) The entomological
- inoculation rate and *Plasmodium falciparum* infection in African children. *Nature* 438,
 492-495.
- 597 13. Bellan, S. E., Dushoff, J., Galvani, A. P. & Meyers, L. A. (2015) Reassessment of HIV-1
 598 acute phase infectivity: accounting for heterogeneity and study design with simulated
- 599 cohorts. *PLOS Med.* **12**, e1001801.
- 600 14. Gomes, M. G. M., et al. (2019) Introducing risk inequality metrics in tuberculosis policy
 601 development. *Nat. Commun.* 10, 2480.
- 602 15. Corder, R. M., Ferreira, M. U. & Gomes, M. G. M. (2020) Modelling the epidemiology
 603 of residual Plasmodium vivax in a heterogeneous host population: a case study in the
 604 Amazon Basin. *PLOS Comput. Biol.* 16, e1007377.
- 605 16. Halloran, M. E., Longini, I. M. Jr. & Struchiner, C. J. (1996) Estimability and
- 606 interpretability of vaccine efficacy using frailty mixing models. *Am. J. Epidemiol.* 144,
 607 83-97.
- 608 17. O'Hagan, J. J., Hernán, M. A., Walensky, R. P. & Lipsitch, M. (2012) Apparent
- 609 declining efficacy in randomized trials: Examples of the Thai RV144 HIV vaccine and
- 610 CAPRISA 004 microbicide trials. *AIDS* **26**, 123.
- 611 18. Gomes, M. G. M., et al. (2014) A missing dimension in measures of vaccination
 612 impacts. *PLOS Pathog.* 10, e1003849.
- 613 19. Gomes, M. G. M., Gordon, S. B. & Lalloo, D. G. (2016) Clinical trials: the mathematics
 614 of falling vaccine efficacy with rising disease incidence. *Vaccine* 34, 3007.
- 615 20. Langwig, K. E., et al. (2017) Vaccine effects on heterogeneity in susceptibility and
- 616 implications for population health management, *mBio* **8**, e00796-17.
- 617 21. Pessoa, D., et al. (2016) Unveiling time in dose-response models to infer host
- 618 susceptibility to pathogens. *PLOS Comput. Biol.* **10**, e1003773.
- 619 22. King, J. G., Souto-Maior, C., Sartori, L. M., Maciel-de-Freitas, R. & Gomes, M. G. M.
- 620 (2018) Variation in *Wolbachia* effects on *Aedes* mosquitoes as a determinant of
- 621 invasiveness and vectorial capacity. *Nat. Commun.* 9, 1-8.

- 622 23. Gomes, M. G. M., et al. (2020) Individual variation in susceptibility or exposure to
- 623 SARS-CoV-2 lowers the herd immunity threshold. *medRvix*
- 624 10.1101/2020.04.27.20081893.
- 625 24. World Health Organization (2021) COVID-19 weekly epidemiological update:
- 626 https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---
- 627 <u>13-july-2021</u>.
- 628 25. Gomes, M. G. M., Ferreira, M. U., Chikina, M., Pegden, W. & Aguas, R. (2021) Frailty
 629 variation models for susceptibility and exposure to SARS-CoV-2. *medRvix*
- 630 10.1101/2021.05.25.21257766.
- 631 26. Diekmann, O., Heesterbeek, J. A. P. & Metz, J. A. J. (1990) On the definition and
- 632 computation of the basic reproduction ratio R_0 in models for infectious diseases in 633 heterogeneous populations. J. Math. Biol. 28, 365-382.
- 634 27. McAloon, C., et al. (2020) Incubation period of COVID-19: a rapid systematic review
 635 and meta-analysis of observational research. *BMJ Open* 10, e039652.
- 636 28. Nishiura, H., Linton, N. M. & Akhmetzhanov, A. R. (2020) Serial interval of novel

637 coronavirus (COVID-19) infections. Int. J. Infect. Dis. 93, 284-6.

- 638 29. Lauer, S. A., et al. (2020) The Incubation Period of Coronavirus Disease 2019 (COVID-
- 639 19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann. Intern.*640 *Med.* 172, 577-582.
- 641 30. Li, Q., et al. (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus642 infected pneumonia. *N. Engl. J. Med.* 382, 1199-1207.
- 643 31. Wei, W. E., et al. (2020) Presymptomatic Transmission of SARS-CoV-2 Singapore,
- 644 January 23–March 16, 2020. *MMWR Morb. Mortal. Wkly. Rep.* 69, 411-415.
- 645 32. To, K. K. W., et al. (2020) Temporal profiles of viral load in posterior oropharyngeal
- 646 saliva samples and serum antibody responses during infection by SARS-CoV-2: an
- 647 observational cohort study. *Lancet Infect. Dis.* **20**, 565-74.
- 648 33. Arons, M. M., et al. (2020) Presymptomatic SARS-CoV-2 Infections and Transmission
- 649 in a Skilled Nursing Facility. *N. Engl. J. Med.* **382**, 2081-2090.

- 650 34. He, X., et al. (2020) Temporal dynamics in viral shedding and transmissibility of
- 651 COVID-19. Nat. Med. 26, 672-675.
- 652 35. Ward, H., et al. (2021) SARS-CoV-2 antibody prevalence in England following the first
 653 peak of the pandemic. *Nat. Commun.* 12, 905.
- 654 36. Novozhilov, A. S. (2008) On the spread of epidemics in a closed hoterogeneous
- 655 population. Math. Biosci. 215, 177-185.
- 656 37. Montalbán, A., Corder, R. M. & Gomes, M. G. M. (2020) Herd immunity under
 657 individual variation and reinfection. *arXiv* 200800098v2.
- 658 38. Pastor-Satorras, R. & Vespignani, A. (2001) Epidemic dynamics and endemic states in
 659 complex networks. *Phys. Rev. E* 63, 066117.
- Miller, J. C., Slim, A. C. & Volz, E. M. (2012) Edge-based compartmental modelling for
 infectious disease spread. *J. R. Soc. Interface* 9, 890-906.
- 662 40. Britton, T., Ball, F. & Trapman, P. (2020) A mathematical model reveals the influence
 663 of population heterogeneity on herd immunity to SARS-CoV-2. *Science* 369, 846-849.
- 664 41. Hartnett, K. (2020) The tricky math of herd immunity for COVID-19. *Quanta Magazine*.
- 665 https://www.quantamagazine.org/the-tricky-math-of-covid-19-herd-immunity-
- 666 20200630/
- 667 42. Aschwanden, C. (2021) Five reasons why COVID herd immunity is probably
- 668 impossible. *Nature* **591**, 520-522. <u>https://www.nature.com/articles/d41586-021-00728-2</u>
- 43. Hall, et al. (2021) SARS-CoV-2 infection rates of antibody-positive compared with
- antibody-negative health-care workers in England: a large, multicentre, prospective
 cohort study (SIREN). *Lancet* 397, 1459-1469.
- 672 44. Flaxman, S., et al. (2020) Estimating the effects of non-pharmaceutical interventions on
 673 COVID-19 in Europe. *Nature* 584, 257-261.
- Keeling, M. J., et al. (2020) Fitting to the UK COVID-19 outbreak, short-term forecasts
 and estimating the reproductive number. *medRvix* 10.1101/2020.08.04.20163782.
- 676 46. Viana, J. et al. (2021) Controlling the pandemic during the SARS-CoV-2 vaccination
- 677 rollout. Nat. Commun. 12, 3674.

- 47. Wood, S. N. (2021) Inferring UK COVID-19 fatal infection trajectories from daily
 mortality data: Were infections already in decline before the UK lockdowns? *Biometrics*10.1111/biom.13462
- 681 48. Bertuzzo, E. et al. (2020) The geography of COVID-19 spread in Italy and implications
 682 for the relaxation of confinement measures. *Nat. Commun.* 11, 4264.
- 683 49. López, L. & Rodó, X. (2021) A modified SEIR model to predict the COVID-19
- 684 outbreak in Spain and Italy: Simulating control scenarios and multi-scale epidemics.
- 685 *Results Phys.* **21**, 103746.